Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer - a Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System

Erstveröffentlichung
2010Authors
Lux, Michael P.
Wöckel, Achim
Benedict, Agnes
Buchholz, Stefan
Kreif, Noemi
Wissenschaftlicher Artikel
Published in
Onkologie ; 33 (2010), 4. - S. 155-166. - ISSN 0378-584X. - eISSN 1423-0240
Link to publication
https://dx.doi.org/10.1159/000286233Institutions
UKU. Klinik für Frauenheilkunde und GeburtshilfeSubject headings
[Free subject headings]: Anastrozole | Cost-effectiveness analysis | Cost-utility analysis | Incremental cost-effectiveness ratio | Tamoxifen | QALY | POSTMENOPAUSAL WOMEN | AROMATASE INHIBITORS | ENDOCRINE THERAPY | UTILITIES | LETROZOLE | MORTALITY[DDC subject group]: DDC 610 / Medicine & health